SEC Form 4 · accession 0001140361-16-076984
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew H Galligan
Officer — Chief Financial Officer
Period of report
Aug 15, 2016
Accepted (ET)
Aug 17, 2016 · 11:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2016 | M | 79 | $3.60 | A | 30,079 | D | |
| Common Stock | Aug 15, 2016 | M | 2,374 | $3.60 | A | 32,453 | D | |
| Common Stock | Aug 15, 2016 | M | 5,047 | $18.00 | A | 37,500 | D | |
| Common StockF2 | Aug 15, 2016 | S | 4,206 | $97.3895 | D | 33,294 | D | |
| Common StockF3 | Aug 15, 2016 | S | 3,194 | $98.0859 | D | 30,100 | D | |
| Common Stock | Aug 15, 2016 | S | 100 | $98.85 | D | 30,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $3.60 | Aug 15, 2016 | M | 79 | D | — | Sep 28, 2021 | Common Stock | 79 | 62,861 | D |
| Stock Option (right to buy)F5 | $3.60 | Aug 15, 2016 | M | 2,374 | D | — | May 14, 2023 | Common Stock | 2,374 | 42,430 | D |
| Stock Option (right to buy)F6 | $18.00 | Aug 15, 2016 | M | 5,047 | D | — | Nov 4, 2024 | Common Stock | 5,047 | 46,852 | D |
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $96.73 to $97.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.73 to $98.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4100% of the shares subject to the option are fully vested and exercisable.
- F51/48th of the shares subject to the option vest on each monthly anniversary measured from May 15, 2013 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- F61/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.